The IDM has curated a go-to range of reliable information to guide and assist staff and students during this time of crisis. We are continuously updating the various COVID-19 resources listed on our webpage below.
The IDM - a cross-faculty, multidisciplinary postgraduate health research institute
Based on the UCT Faculty of Health Sciences campus in a 7,100 sqm state-of-the-art facility, we operate in the fields of infectious diseases and molecular medicine.
Clinical research relevant to the needs of Africa's people
The IDM influences health policy and practice by translating our scientific discoveries and applying them in various communities; community relationships and trust are critical.
Capacity building in the IDM
The largest research entity at UCT, the IDM is a national leader in research and health sciences human capital development.
IDM driving world class research
We conduct research at the laboratory-clinic-community interface by engaging a wide range of scientific and clinical disciplines; with 62 consortia linking us with 183 institutions in 22 African countries and 24 countries beyond.
University accredited research institute - Tackling diseases of importance in Africa - Developing people - Impacting health policy and practice
Here’s a different reason for tobacco to be in the news. Cape Bio Pharms, a biotech company with its origins in the Biopharming Research Unit (BRU) at the University of Cape Town (UCT), has joined the global effort to create a fast and affordable antibody test for COVID-19, using a relative of the tobacco plant.
South Africa can become a country that rationally adapts to a COVID-19-integrated world, taking into account all healthcare priorities, to the benefit of all her people, write academics from the University of Cape Town (UCT).
With more than seven million HIV-infected citizens, South Africa has one of the largest and arguably most successful antiretroviral therapy programmes in the world. Continuous involvement in this programme has the potential to increase the life expectancy of those living with HIV by more than a decade. However, sustaining engagement along the HIV care continuum has proven challenging and there is the risk that many may disengage and be lost to follow-up care.
Researchers from the South African Tuberculosis Vaccine Initiative (SATVI) at the University of Cape Town (UCT), the Center for Global Infectious Disease Research – Seattle in the United States, and a large consortium of collaborators have developed a validated a new, simple blood-based test that has the potential to serve multiple functions in the fight against TB.
